


## European Medicines Agency's support to SMEs

European Access Academy Fall Convention Joint EAA & EUCOPE Preconvention SME 6 November 2025

Presented by **Constantinos Ziogas, Head of SME Office** Regulatory Science and Innovation Task Force (TRS) European Medicines Agency

## **EMA** interactions across the medicine life cycle





## SME office




Set up by Commission Regulation (EC) No 2049/2005 (SME Regulation)





Provides advice, guidance and assistance to SMEs to support the development of medicines in the European Union (EU) and the European Economic Area (EEA).







SME@ema.europa.eu



SME Helpline :+31 (0)88 781 8787



Support to SMEs | European Medicines Agency (EMA)





### **EMA SME status**




# **EU SME Definition - Commission** recommendation 2003/361/EC

Size and ownership structure

### Size

- micro,
- small,
- medium-sized



- partner
- linked



# 2,000 SMEs registered – Facts and figures

### Location

12.2%

10.5%

7.9%

6.4%

6.1%


6%

5.5%

9.1%

### Company activity





### Profile

#### 12,5% Academic spin-offs

**79,8%** of companies' activities in the pharmaceutical sector

17,4% in the pharmaceutical and medical devices sector

2,8% in the medical devices sector

**59%** of companies operating in the pharmaceutical sector have products at development stage



### SME Office activities



Assignment and renewal of SME status

Compliance review of applications



Regulatory assistance

Guidance & advice



SME briefing meetings

Early dialogue and discussion on regulatory strategy for product development



Fee incentives

Scientific advice, inspections, marketing authorisation dossiers



Translation of product information in all EU languages

Free of charge, at time of marketing authorisation



Training and engagement

Info days, SME newsletters and targeted mailings to SMEs



# Regulatory assistance



### **Key topics**

SME definition, incentives and services

Early development advice and routing (scientific advice, ITF, PRIME)

Regulatory topics (e.g. legal basis, data protection)

Criteria for orphan designation, market exclusivity


Paediatric requirements

Clinical trials, CTIS



### **Tools**

Via email <u>SME@ema.europa.eu</u>
Via SME helpline + 31 (0)88 781 8787






# SME briefing meetings



- Discussion and guidance on regulatory strategy of one or several products
- Platform for early informal dialogue
- Interdisciplinary EMA team
- 90 minutes
- Free of charge
- Minutes with outcome of discussions and follow-up guidance

Topics: e.g. Scientific Advice, Orphan Drug Designation, Pediatric investigation plan, PRIME



Year	Average N. of meetings
2006-2010	5
2011-2015	9
2016-2020	13
2021-2024	6



### Fee incentives for SMEs



Scientific advice: 90% fee reduction / 100% for designated orphan products



### Marketing authorisation application:

Fee deferral until the outcome 100% fee reduction for designated orphan products

Conditional fee exemption



**Inspections** (pre-authorisation):

90% fee reduction and deferral

100% fee reduction for designated orphan products



**Inspections** (post-authorisation):

90% fee reduction

100% fee reduction for designated orphan products



**Pharmacovigilance :** 100% fee reduction for micro-sized enterprises, 40% fee reduction for small or medium-sized enterprises



**Post-authorisation procedures:** 100% fee reduction for microsized enterprises, 40% fee reduction for small or medium-sized enterprises



# Use of EMA supporting tools for medicines development

### Scientific advice (H)

25%

154 out of 625 requests from SMEs

### **Protocol assistance (H)**

39%

51 out of 131 requests from SMEs

### Qualification of novel methodologies

36%

5 out of 14 requests from SMEs

#### **Veterinary scientific advice**

26%

7 out of 27 requests from SMEs

#### **Innovation Task Force (ITF)**



**14** out of 34 briefing **meetings** with **ITF** from SMEs

#### **PRIME**



**6** out of 18 **PRIME positive** eligibility recommendations from SMEs

#### **Advanced therapies**



**19** out of 52 recommendations for **advanced therapy classification** for SMEs

**1** ATMP certification (3 submitted)



# SME marketing authorisations (2024)

#### **Human medicines**

87.5% success rate



#### 10 initial submissions


#### 7 positive opinions of which

- 2 new active substances,
- 1 orphan medicine
- 1 authorisation under exceptional circumstances

Therapeutic areas: oncology, endocrinology, pneumology/allergology, ophthalmology, cardiovascular diseases

Longer approval times for SMEs applications (ANNUAL REPORT 2024)

→ Use and follow Scientific Advice to increase success rate of marketing authorisation applications





# Training&education and engagement with partners and stakeholders

### **Training&awareness**

Facilitating access to regulatory and scientific information



Info days &training





SME newsletter, mailings

**Subscribe** 



### **Engage** with partners and stakeholders



Participation to conferences













SME user guide

# Training&education











**9** participations to conferences or lectures in 2024

Conferences and lectures to raise awareness





### The past 5 years:

SME Info Day on VETS

2021.10.28

EMA support for innovative veterinary medicines, vet regulation, PV, UPD

**EMA-EIC Info day** 

2023.01.31

EMA support to innovation (PRIME, SA, ITF)

SME Info day

2024.10.18

Clinical trials, HTA, Medical devices, NFR, shortages





SME and academia webinar on CTR - CTIS

2021.11.29

CTR, CTIS functionalities

Awareness session for SMEs new pharma legislation

2023.11.24

Pharma package, impact on SMEs, Q&A



# Engagement with partners&stakeholders





Mutual exchange and support on SME definition




Sharing experience on SME support



Mutual exchange and support on SME definition







#### **DG GROW/DG SANTE**

Mutual exchange and support on SME definition and EU initiatives (e.g. revision of SME definition; EU Biotech and biomanufacturing Hub).





# Thank you

constantinos.ziogas@ema.europa.eu

Follow us







